BIO08021 2011 RECOMBINANT DRUG DEVELOPMENT AND ENGINEERING
Full Title
RECOMBINANT DRUG DEVELOPMENT AND ENGINEERING
Transcript Title
RECOMBINANT DRUG ENGINEERING
Code
BIO08021
Attendance
N/A %
Subject Area
BIO - Bio Tech/Eng/Chem
Department
LIFE - Life Sciences
Level
08 - NFQ Level 8
Credit
05 - 05 Credits
Duration
Semester
Fee
€
Start Term
2011 - Full Academic Year 2011-12
End Term
2014 - Full Academic Year 2014-15
Author(s)
Kieran Tobin, Tony McCabe
Programme Membership
SG_SBIOP_K08 201100 Bachelor of Science (Honours) in Biopharmaceutical Science.
SG_SBIOP_E08 201100 Level 8 Certificate in Science in Biopharmaceutical Science
SG_SBIOP_E08 201100 Level 8 Certificate in Science in Biopharmaceutical Science
SG_SBIOP_E08 201100 Level 8 Certificate in Science in Biopharmaceutical Science
SG_SBIOT_E08 201500 Certificate in Science in Bioprocessing Technologies SG_SBIOT_E08
Description
The subject aim is to introduce the students to the drug discovery and development process. The subject will compare traditional pharmaceutical drug development to biopharmaceutical drug development. The module will include an in depth study of the different modes and methods of recombinant protein expression in different cellular hosts. The module will introduce the analysis and manipulation of recombinant protein expression in the biopharmaceutical sector.
Learning Outcomes
On completion of this module the learner will/should be able to;
1.
Differentiate between irrational and rational drug design. Describe the methods of drug target identification and validation.
2.
Outline the molecular methods and components required to characterize and clone the gene of interest.
3.
Categorize the essential steps in the design and regulation of a recombinant expression system.
4.
Describe methods employed to optimize nucleic acid sequence and cell expression systems for maximum protein expression including methods to optimize the molecular characteristics of purified proteins
5.
Examine methods of verifying the functional and molecular characteristics of the recombinant protein.
6.
Illustrate methods of production of humanized monoclonal antibodies and phage display libraries.
7.
Perform analysis of a recombinant protein
Module Dependencies
Prerequisites
Molecular Biology
Co-requisites
None
Incompatibles
None
Indicative Syllabus
Drug Discovery.
Overview of key molecular biological processes and techniques.
Recombinant protein expression.
Recombinant protein analysis, characterization and manipulation.
Recombinant expression experiments in cell lines by different techniques.
Coursework & Assessment Breakdown
Coursework & Continuous Assessment
70 %
End of Semester / Year Formal Exam
30 %
Coursework Assessment
| Title | Type | Form | Percent | Week | Learning Outcomes Assessed | |
|---|---|---|---|---|---|---|
| 1 | Continuous Assessment Short questions on theory lecture content. | Continuous Assessment | UNKNOWN | 15 % | Week 4 | 1,2,3,4 |
| 2 | Practical Evaluation Short questions on experimental data | Continuous Assessment | UNKNOWN | 15 % | Week 8 | 7 |
| 3 | Individual Project Literature project | Continuous Assessment | UNKNOWN | 40 % | OnGoing | 2,3,4,5,6 |
End of Semester / Year Assessment
| Title | Type | Form | Percent | Week | Learning Outcomes Assessed | |
|---|---|---|---|---|---|---|
| 1 | Essay Theory exam | Final Exam | UNKNOWN | 30 % | End of Term | 1,2,3,4,5,6,7 |
Part Time Mode Workload
| Type | Location | Description | Hours | Frequency | Avg Workload |
|---|---|---|---|---|---|
| Lecture | Distance Learning Suite | Online lectures | 2 | Weekly | 2.00 |
| Independent Learning | Not Specified | Project work and study | 5.5 | Weekly | 5.50 |
Total Part Time Average Weekly Learner Contact Time 2.00 Hours
Module Resources
Non ISBN Literary Resources
Biotechnology and Biopharmaceuticals: Transforming Genes into Drugs. Author: Rodney, J.Y.Ho. Wiley-Liss 2003
Gene Cloning and DNA Analysis: An Introduction. Author Brown, T.A. Oxford Blackwell 2006
Drugs: From Discovery to Approval. Author: Rick, N.G., Wiley-Liss Press. 2004
Other Resources
None
Additional Information
None